AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1579938
Drug: Piroxicam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (40 mg preoperatively, 40 mg on the day of surgery, 20 mg on days 1 and 2)
Trial: 31417163
Drug: Neuraminidase inhibitors
RxNorm normalized name: Neuraminidase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuraminidase inhibitors (NAIs)
Trial: 27605365
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (SC) + Text Messaging (TM) + Adherence-focused Behavioral Therapy (ABT)
Trial: 21193066
Drug: Community-wide isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Community-wide isoniazid preventive therapy (IPT) offered to all employees
Trial: 20214205
Drug: 20% Albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Albumin 100 ml every 12 hours
Trial: 20214205
Drug: 6% hydroxyethylstarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethylstarch 250 ml every 6 hours
Trial: 16632238
Drug: Gliclazide (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide (160 mg daily for 4 weeks)
Trial: 16632238
Drug: Glibenclamide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (5 mg daily for 4 weeks)
Trial: 16632238
Drug: Gliclazide and
RxNorm normalized name: Gliclazide and metformin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide and Glibenclamide (both treatments)
Trial: 12730416
Drug: -ISO (soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: -ISO (soy protein with 3 mg isoflavones)
Trial: 1689679
Drug: Surgical biliary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical biliary bypass followed by synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in Group 1.
Trial: 1689679
Drug: Synchronous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in Group 2.
Trial: 1689679
Drug: Synchronous therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synchronous therapy (10 intravenous administrations of 5-fluorouracil 750 mg/m2 over 8 h, followed by radiation with 400 rads every 4 days) in both groups.
Trial: 6987582
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg potassium penicillin or erythromycin ethylsuccinate q.i.d.
Trial: 29069153
Drug: Codeine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine (30 mg) plus acetaminophen (500 mg), every 4 h, for 3 days
Trial: 29069153
Drug: Tramadol hydrochloride
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tramadol hydrochloride (37.5 mg) plus acetaminophen (500 mg), every 4 h, for 3 days
Trial: 21982651
Drug: Darapladib (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darapladib (160 mg enteric-coated tablet daily)
Trial: 8779124
Drug: Long term
RxNorm normalized name: BENZETHONIUM CHLORIDE 0.12 g in 100 mL TOPICAL SOLUTION [CA-REZZ - LONG TERM CARE - INCONTINENT CLEANSER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long term steroid treatment (group L) for at least 18 months
Trial: 8779124
Drug: Selective treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective treatment (group S) reserved for symptoms or deteriorating lung function
Trial: 6859300
Drug: Abstinence therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence therapy
Trial: 31520576
Drug: Aripiprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole (10 mg single oral dose)
Trial: 26966829
Drug: Kinesio Taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio Taping (KT) in combination with counseling and jaw exercise
Trial: 25134002
Drug: Caffeine 3
RxNorm normalized name: caffeine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 3 mg·kg body mass
Trial: 25134002
Drug: Caffeine 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 4.5 mg·kg body mass
Trial: 14715864
Drug: Glibenclamide (10.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (10.5 mg)
Trial: 14715864
Drug: Repaglinide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (8 mg)
Trial: 8214179
Drug: Group psychotherapy
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group psychotherapy (90-minute weekly sessions for 10 weeks)
Trial: 3304367
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate 40 mg twice a day
Trial: 30003027
Drug: S-Ketamine (initial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-Ketamine (initial bolus 1 mg/kg and continuous infusion of 0.015625 mg/kg/min with dosage reduction -10%/10 min)
Trial: 27043952
Drug: Trauma-Focused Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trauma-Focused Cognitive Behavioral Therapy (Tf-CBT)
Trial: 24878085
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + metformin (850 mg three times a day)
Trial: 24878085
Drug: Chemotherapy +
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy + metformin
Trial: 18047502
Drug: DVPX 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DVPX 250 mg
Trial: 12829154
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus amifostine (340 mg/m2 i.v., 15 min before RT)
Trial: 7438385
Drug: Naloxone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.2 mg/kg over 1 minute
Trial: 29891906
Drug: Natural hirudin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural hirudin and subcutaneous LMWH-calcium (test group)
Trial: 29891906
Drug: Subcutaneous LMWH-calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous LMWH-calcium (control group)
Trial: 25473882
Drug: GSK1265744 (744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg subcutaneously
Trial: 25473882
Drug: GSK1265744 (744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 200 mg IM
Trial: 25473882
Drug: GSK1265744 (744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (744) LA 800 mg IM followed by 3 monthly doses of 400 mg IM
Trial: 25473882
Drug: GSK1265744 (744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK1265744 (744) LA 800 mg IM followed by a second injection of 800 mg IM after 12 weeks
Trial: 25473882
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) LA 1200 mg IM at month 3 and 900 or 600 mg IM at month 4
Trial: 6763435
Drug: Oral prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisone, 10 mg thrice daily, continued until clinical remission, maximally 12 weeks.
Trial: 29436064
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of amitriptyline at bedtime for 2 months
Trial: 27161894
Drug: Cholecalciferol (50,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol (50,000 IU twice weekly)
Trial: 27161894
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 drops of a placebo solution twice weekly)
Trial: 26466328
Drug: Salbutamol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (400 μg)
Trial: 22457014
Drug: Ipratropium (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium (80 μg)
Trial: 16042675
Drug: Gemfibrozil (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemfibrozil (600 mg) and Itraconazole (100 mg, first dose 200 mg)
Trial: 12353302
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily warfarin
Trial: 12353302
Drug: Variable dose
RxNorm normalized name: methohexital
DrugBank: Methohexital (DB00474)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable dose warfarin (PT 1.3‐1.5 times the normal PT)
Trial: 10419991
Drug: Prenatal supplements
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal supplements containing iron + folate + zinc (15 mg zinc)
Trial: 10419991
Drug: Prenatal supplements
RxNorm normalized name: Ardisia crenata root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenatal supplements containing iron + folate (without zinc)
Trial: 7480534
Drug: Capsule associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule associated with high frequency of reinforcement (greater monetary payoff)
Trial: 7480534
Drug: Capsule associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule associated with low frequency of reinforcement (lower monetary payoff)
Trial: 7480534
Drug: Self-administration results
RxNorm normalized name: omega-3 acid ethyl esters (USP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration results
Trial: 2124648
Drug: Piperazine oestrone
RxNorm normalized name: Piperazine
DrugBank: Piperazine (DB00592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Piperazine oestrone sulphate (PE1S, 2.5 mg/day)
Trial: 2124648
Drug: Oestradiol valerate
RxNorm normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestradiol valerate (E2V, 2.0 mg/day)
Trial: 2124648
Drug: PE1S in
RxNorm normalized name: Immunoglobulin g 1 (human monoclonal pe1-1 anti-hepatitis b virus surface antigen), disulfide with human monoclonal pe1-1 .lambda.-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PE1S in combination with levonorgestrel (LNG, 250 micrograms/day)
Trial: 6770707
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium cromoglycate (200 mg four times daily for 4 weeks)
Trial: 30039199
Drug: Cilostazol 100
RxNorm normalized name: cilostazol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol 100 mg oral dose
Trial: 28616765
Drug: 150 g
RxNorm normalized name: TOCOPHEROL 2 g in 150 g TOPICAL OIL [TUREMRIC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 g kg‐1 RSM
Trial: 28616765
Drug: 450 g
RxNorm normalized name: IODINE 450 g in 10 L TOPICAL LIQUID [UDDERBLEND]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 g kg‐1 RSM
Trial: 28616765
Drug: 600 g
RxNorm normalized name: PETROLATUM 600 g in 1000 g TOPICAL OINTMENT [EltaMD Laser Balm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 g kg‐1 RSM
Trial: 28616765
Drug: 450 g
RxNorm normalized name: IODINE 450 g in 10 L TOPICAL LIQUID [UDDERBLEND]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 450 g kg‐1 RSM and 600 g kg‐1 RSM
Trial: 26222270
Drug: Treatment aiming
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment aiming at normoglycemia (n = 33)
Trial: 23537332
Drug: Telemonitoring intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telemonitoring intervention (daily self-measurements of respiratory-rate, heart-rate, blood pressure, oxygen saturation, weight, body temperature, and health status questionnaire)
Trial: 16860830
Drug: DEC alone
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC alone (6 mg/kg)
Trial: 16860830
Drug: DEC and
RxNorm normalized name: insulin degludec and liraglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC and albendazole (400 mg)
Trial: 16860830
Drug: DEC alone
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC alone (6 mg/kg) and DEC and albendazole (400 mg)
Trial: 8311536
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg oestradiol-valerate
Trial: 3013044
Drug: Fentanyl (0.005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (0.005 mg/kg b.w.)
Trial: 3013044
Drug: Buprenorphine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.01 mg/kg b.w.)
Trial: 3013044
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of fentanyl and buprenorphine
Trial: 29912266
Drug: Monthly active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly active asking
Trial: 29912266
Drug: Daily self-report
RxNorm normalized name: DAILY SELF DISCOVERY SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily self-report diary entries
Trial: 29912266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of active asking and diaries
Trial: 29912266
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of active asking and hotline
Trial: 28407657
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids and vitamin E co-supplementation (1,000 mg omega-3 from flaxseed oil containing 400 mg α-Linolenic acid plus 400 IU vitamin E)
Trial: 23748748
Drug: Ritonavir (0.1-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (0.1-300 mg)
Trial: 19912513
Drug: Oral vitamin
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin K (1 mg) on the day before surgery (group K)
Trial: 19912513
Drug: Heparin bridging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin bridging after the last VKA dose on day -5 before surgery (group H)
Trial: 16856145
Drug: Rasagiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (1 mg/2 mg); n = 38
Trial: 16856145
Drug: Rasagiline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (0.5 mg/day); n = 22
Trial: 16856145
Drug: Rasagiline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rasagiline (1 mg/day); n = 12
Trial: 10906651
Drug: Pulsed-dye laser
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed-dye laser (PDL) therapy (585 nm)
Trial: 10906651
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (liquid nitrogen cryotherapy or cantharidin)
Trial: 8854792
Drug: Continuous hyperthermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in saline
Trial: 8854792
Drug: Continuous hyperthermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperthermic pleural perfusion (CHPP) with 100 mg CDDP diluted in distilled water
Trial: 6443596
Drug: 1 ml/20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 ml/20 kg saline (Control)
Trial: 30588947
Drug: Combined intrarectal
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intrarectal lidocaine gel and periprostatic nerve block (cGPNB)
Trial: 21884013
Drug: Ambrisentan 5
RxNorm normalized name: ambrisentan 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambrisentan 5 mg once daily for 24 weeks
Trial: 20580035
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/d) for 20 weeks
Trial: 20580035
Drug: Rosuvastatin/exercise (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin/exercise (10 mg/d + exercise training 3d/wk from week 10 to week 20)
Trial: 20580035
Drug: Rosuvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (10 mg/d) and Rosuvastatin/exercise (10 mg/d + exercise training) combined
Trial: 18007551
Drug: Metformin 500mg
RxNorm normalized name: METFORMIN 500MG/SITAGLIPTIN 50MG TAB
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg tid for 6 months
Trial: 16121967
Drug: Clazosentan (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (0.2 mg/kg/hr)
Trial: 16121967
Drug: Clazosentan (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clazosentan (0.4 mg/kg/hr for 12 hours followed by 0.2 mg/kg/hr)
Trial: 11835038
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 14 days
Trial: 10999124
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (400 mg/day for six weeks) in Group I
Trial: 1524655
Drug: Haloperidol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (0.5 mg/kg)
Trial: 1524655
Drug: Reduced haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced haloperidol (0.5 mg/kg)
Trial: 1524655
Drug: Haloperidol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10 mg) twice daily for 4 weeks
Trial: 3886566
Drug: Diltiazem in
RxNorm normalized name: diltiazem Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem in combination with diuretics
Trial: 3886566
Drug: Diltiazem in
RxNorm normalized name: diltiazem Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem in combination with other drugs
Trial: 31295074
Drug: Biofilm-disrupting gel
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biofilm-disrupting gel (BlastX) plus debridement (standard of care)
Trial: 31295074
Drug: Triple-antibiotic maximum-strength
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-antibiotic maximum-strength ointment (standard of care)
Trial: 31295074
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to biofilm-disrupting gel after 4 weeks of standard care
Trial: 25293665
Drug: Transcranial laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial laser therapy
Trial: 20650346
Drug: Chitosan (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chitosan (750 mg, 3 times per day) 30 minutes before meals
Trial: 16842799
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens 0.625 mg (CEE)
Trial: 18365858
Drug: 17 beta‐estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Trial: 11915588
Drug: Raloxifene HCl
RxNorm normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raloxifene HCl 60 mg
Trial: 12095385
Drug: Abacavir, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir, 300 mg twice per day, while continuing all other antiretroviral therapy (n = 54)
Trial: 12095385
Drug: Continuing all
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuing all antiretroviral therapy (n = 57)
Trial: 3169489
Drug: Pectin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin (15 g added to meal)
Trial: 3169489
Drug: Methylcellulose (15
RxNorm normalized name: methylcellulose (15 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylcellulose (15 g added to meal, control)
Trial: 30201324
Drug: 0.5 μg.kg−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 μg.kg−1 of dexmedetomidine (high Dex group)
Trial: 30201324
Drug: 0.25 μg.kg−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 μg.kg−1 of dexmedetomidine (low Dex group)
Trial: 23159100
Drug: Aggressive statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive statin therapy
Trial: 16817556
Drug: Graded dermal
RxNorm normalized name: Dermal-Soothe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded dermal tuberculin test using 100%, 25%, 5%, and 1% tuberculin solution via prick test
Trial: 12694144
Drug: Adrenaline 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 0.5 micro g.ml‐1
Trial: 12694144
Drug: Adrenaline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 1.0 micro g.ml‐1
Trial: 12694144
Drug: Adrenaline 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 1.5 micro g.ml‐1
Trial: 12694144
Drug: Adrenaline 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline 2.0 micro g.ml‐1 (standard mixture)
Trial: 3794300
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 40 micrograms HBsAg (months 0, 1, 6)
Trial: 3794300
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of 10 micrograms HBsAg (healthy controls)
Trial: 3794300
Drug: 6 doses
RxNorm normalized name: interferon alfa-2b,recomb. 3 million unit/0.2 mL (6 doses per pen = 18 million unit) SUBCUT PEN INJECTOR KIT (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 doses of 40 micrograms HBsAg (monthly intervals)